Analytical Data
-
Gene name
XAGE1A
- Application
-
Alternative Names
XAGE1A；GAGED2；X antigen family member 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HD64
-
Expression Region
1-81aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMESPKKK NQQLKVGILH LGSRQKKIRI QLRSQCATWK VICKSCISQT PGINLDLGSG VKVKIIPKEE HCKMPEAGEE QPQV
-
Molecular Weight
12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
XAGE1A is a member of the XAGE (X antigen gene) family and has garnered attention due to its role in cancer immunology. It is primarily expressed in various tumors, including melanoma and other malignancies, while being largely absent in normal tissues, making it a promising target for cancer immunotherapy. XAGE1A is classified as a cancer-testis (CT) antigen, which typically elicits immune responses in individuals with tumor presence but is not expressed in adult somatic tissues outside of germ cells. This unique expression pattern highlights its potential as a biomarker for tumor detection and as a target for vaccine development. Recent studies have focused on characterizing the recombinant protein of XAGE1A to explore its immunogenic properties, with the goal of enhancing T-cell responses in cancer patients. By using techniques such as recombinant DNA technology and protein expression in suitable systems, researchers aim to produce a functional form of XAGE1A that can be used in clinical applications. The understanding of its structure, expression, and interaction with the immune system is critical for developing novel immunotherapeutic strategies. Overall, the research on XAGE1A recombinant protein continues to be a promising area in the field of cancer biology, providing insights into potential therapeutic interventions aimed at harnessing the body's immune system to combat cancer.
